On March 30, 2025 Jecho Laboratories, Inc. reported it will present three proprietary progams in poster format at the 2025 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Jecho Laboratories, MAR 30, 2025, View Source [SID1234653896]). The featured innovations include:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Development of JLF025: an optimized anti-mesothelin T-cell engager for enhanced safety and efficacy
Persistent elimination of tumors via balanced regulation of immune signals
Development of an anti-TF ADC with a potentially improved therapeutic index
As one of the world’s largest and most influential cancer research conferences, the 2025 AACR (Free AACR Whitepaper) Annual Meeting will be held April 25–30, 2025, in Chicago.

"These presentations represent a key milestone in Jecho’s growth," said by the Chief Executive Officer of Jecho Laboratories. "We are proud to demonstrate our evolution from a fast follower to a global innovator in drug development. Our team is focused on delivering differentiated therapies that address unmet needs through scientific rigor, targeted design, and a commitment to patient impact."

Details on presentation are below:

Development of an anti-TF ADC with a potentially improved therapeutic index
• Abstract Presentation Number: 348
• Poster Section: 16
• Session Time: April 27, 2025, 2:00 PM – 5:00 PM (U.S. Central Time)
• AACR (Free AACR Whitepaper) Link: View Source!/20273/presentation/3205
Persistent elimination of tumors via balanced regulation of immune signals
• Abstract Presentation Number: 2230
• Poster Section: 38
• Session Time: April 28, 2025, 9:00 AM – 12:00 PM (U.S. Central Time)
• AACR (Free AACR Whitepaper) Link: View Source!/20273/presentation/8429
Development of JLF025, an anti-mesothelin T cell engager optimized for efficacy and safety
• Abstract Presentation Number: 6021
• Poster Section: 35
• Session Time: April 29, 2025, 2:00 PM – 5:00 PM (U.S. Central Time)
• AACR (Free AACR Whitepaper) Link: View Source!/20273/presentation/1929